GO
Loading...

Pfizer Inc

More

  • Midday Glance: Pharmaceuticals companies Monday, 12 Jan 2015 | 1:23 PM ET

    Baxter International Inc. rose$. 28 or. 4 percent, to $72.66. Bristol-Myers Squibb Co. rose $2.74 or 4.5 percent, to $63.06. Hospira rose$. 06 or. 1 percent, to $61.70.

  • Most active New York Stock Exchange-traded stocks Monday, 12 Jan 2015 | 1:23 PM ET

    NEW YORK— A look at New York Stock Exchange 10 most-active stocks at the close of trading:. AK Steel Holding Corp. fell 13.9 percent to $4.65 with 28,602,000 shares traded. Alcoa Inc. rose. 4 percent to $16.17 with 27,574,600 shares traded.

  • Early Glance: Pharmaceuticals companies Monday, 12 Jan 2015 | 10:45 AM ET

    Baxter International Inc. fell$. 13 or. 2 percent, to $72.25. Bristol-Myers Squibb Co. rose $2.03 or 3.4 percent, to $62.35. Hospira fell$. 10 or. 2 percent, to $61.54.

  • Jan 12- Privately held 23 andMe Inc said Pfizer Inc would have access to its research services, helping the pharmaceutical giant better understand the lupus disease. About 5 million people worldwide have a form of lupus, according to the Lupus Foundation of America. Pfizer is already partnering with the company to study genetic factors associated with the...

  • Jan 9- Portola Pharmaceuticals Inc said its experimental drug met the main goal of reversing the effect of an anticoagulant drug in a late-stage study, sending the company's shares up 11 percent in premarket trading. Data showed that an intravenous shot of the drug, andexanet alfa, immediately reversed the anticoagulation activity of Xarelto, developed by...

  • Jan 9- Portola Pharmaceuticals Inc said its experimental drug met the main goal of reversing the effect of Johnson& Johnson's blood thinner, Xarelto, in a late-stage study. Data showed that an intravenous shot of the drug, andexanet alfa, immediately reversed the anticoagulation activity of Xarelto in healthy volunteers aged 50-75 years.

  • Jan 9- An experimental drug from Sanofi SA and Regeneron Pharmaceuticals was found to be effective in lowering "bad" cholesterol even when administered once every four weeks, instead of every two weeks. Sanofi SA and Regeneron are in a fierce race with Pfizer and Amgen Inc to bring their PCSK9 inhibitor to the market, which is expected to be worth billions if these...

  • S&P 500 records longest loss streak since late 2013 Tuesday, 6 Jan 2015 | 4:37 PM ET
    Traders work on the floor of the New York Stock Exchange, Oct. 29, 2014.

    Stocks fell Tuesday as investors fretted the implications of crude's failure to find a floor.

  • It's all about oil, the euro and a strong dollar Monday, 5 Jan 2015 | 10:43 AM ET
    A man walks by a euro sign light installation in Vilnius, Lithuania, on Dec. 31, 2014.

    If the weak euro, strong dollar and cheap oil persist, these commodities and stocks will predictably take a hit.

  • Jan 5- Cempra Inc moved a step closer to approval for its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial. Shares of Cempra, among a clutch of smaller companies developing treatments to fight super-bugs, rose as much as 18 percent to $27.10 in early trading on Monday. WBB Securities' Steve...

  • Jan 5- Cempra Inc moved a step closer to approval of its lead antibiotic, solithromycin, after an oral version of the potential blockbuster met the main goal in a late-stage trial. Data showed solithromycin actually outperformed moxifloxacin by a slight margin, Cempra said on Sunday. North Carolina- based Cempra is also evaluating an intravenous formulation of...

  • Tax inversion anyone? A year in M&A Monday, 29 Dec 2014 | 1:20 AM ET

    Mergers and acquisitions broke a seven-year losing streak in 2014, with $3.48 trillion worth of deals. CNBC looks at some of the year's highlights.

  • Stocks extend holiday cheer: S&P, Dow end at records Friday, 26 Dec 2014 | 4:00 PM ET
    A trader works on the floor of the New York Stock Exchange.

    Stocks rose in light volume on Friday, with the Dow and S&P 500 closing at records.

  • Dec 24- The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc.. Memantine is the active ingredient in Actavis' Namenda, while donepezil is the active ingredient in Pfizer Inc's Aricept. Dublin, Ireland- based Actavis said it expects to launch Namzaric in...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • Fear factor fades as global M&A hits 7-year high Monday, 22 Dec 2014 | 5:47 AM ET

    CEOs got their deal-making mojo back in 2014, emboldened by a clearer outlook for their businesses to take M&As to their highest level since 2007.

  • Midday movers: Microsoft, Rite Aid, Pfizer & more Thursday, 18 Dec 2014 | 12:43 PM ET

    Some of Thursday's midday movers:

  • LONDON, Dec 12- Britain has all the right ingredients for an M&A boom, upbeat company bosses, a vibrant economy and a buoyant stock market, but dealmaking is lagging behind the rest of the world. In Britain, although M&A activity is up compared to 2013, it has been flat for the last five years. Ten years ago, dealmaking in Britain, Europe's financial hub and home to some of...

  • Dec 11- Pfizer Inc's antipsychotic Geodon and generic versions of the drug can trigger a potentially fatal skin reaction, the U.S. Food and Drug Administration warned on Thursday. A new warning has been added to the drug's label to describe the condition- known as Drug Reaction with Eosinophilia and Systemic Symptoms- which may start as a rash and spread all over.